BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BioNTech SE ( (BNTX) ).
On April 11, 2026, BioNTech SE reported positive primary analysis results from a Phase 2 cohort of its HER2-targeted antibody-drug conjugate trastuzumab pamirtecan in patients with advanced, HER2-expressing recurrent endometrial cancer who had progressed after first-line chemotherapy. The data, presented at the 2026 Society of Gynecologic Oncology meeting, showed clinically meaningful antitumor activity across all HER2 expression levels in a heavily pre-treated, real-world-like population.
In 96 centrally HER2-tested patients, the drug achieved a confirmed objective response rate of 47.9% and a median progression-free survival of 8.1 months, with similar efficacy in patients previously treated with checkpoint inhibitors. Among 143 locally tested, efficacy-evaluable patients, response rates ranged from 33.9% in lower HER2 expression (IHC1+) to 73.1% in high expression (IHC3+), with a median duration of response of 10.3 months.
The safety profile was described as manageable and consistent with HER2-targeted ADCs, with mostly low-grade nausea, anemia, platelet reductions and fatigue, and grade 3 or higher interstitial lung disease or pneumonitis in 4.8% of patients, generally manageable with medical interventions. These findings underscore the potential of trastuzumab pamirtecan to address a high unmet medical need in recurrent endometrial cancer, where current chemotherapy offers modest response rates.
Trastuzumab pamirtecan, a third-generation topoisomerase-1 inhibitor-based ADC developed with Duality Biologics, has previously received U.S. FDA Fast Track and Breakthrough Therapy designations for endometrial cancer, reinforcing regulatory momentum. A global confirmatory Phase 3 trial in recurrent endometrial cancer is ongoing, alongside a fully enrolled Phase 3 trial in HER2-low metastatic breast cancer expected to read out this year, signaling a possible expansion of BioNTech’s oncology portfolio beyond mRNA vaccines.
The most recent analyst rating on (BNTX) stock is a Buy with a $155.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
The score is held back primarily by deteriorated profitability and bearish technicals (price below major moving averages with negative MACD). Offsetting factors include strong solvency and liquidity with very low leverage, plus a generally constructive earnings update around pipeline progress and strategic de-risking, though near-term guidance points to lower revenues and higher spend.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global next-generation immunotherapy company specializing in oncology and other serious diseases, leveraging mRNA technologies, antibody-drug conjugates, CAR-T cell therapies and other modalities. The company focuses on developing cancer treatments and infectious disease vaccines, supported by in-house manufacturing and partnerships with major pharmaceutical groups including Pfizer, Genentech and Bristol Myers Squibb.
Its diversified pipeline targets the full continuum of cancer care with mRNA immunotherapies, targeted therapies and innovative cell therapies. BioNTech’s strategy combines computational discovery with clinical development to rapidly advance novel biopharmaceuticals across multiple solid tumor indications and infectious diseases, positioning the company as a key player in advanced oncology therapeutics.
Average Trading Volume: 1,137,488
Technical Sentiment Signal: Sell
Current Market Cap: $24B
Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.
